Two agents that inhibit the PI3K/AKT/PTEN pathway have received regulatory approval for patients with oestrogen receptor (ER)-positive, HER2-negative advanced breast cancer (alpelisib and everolimus), but neither have shown a significant prolongation of overall survival. The gene discussed is ERBB2; the disease is breast cancer.